SCHEMBL9926569

SCHEMBL9926569

Cc1cc(Cl)ccc1CC(=O)N(C)Cc1cccnc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PYGL P06737 1/20 0.52
ERCC1 P07992 1/20 0.49
ERCC4 Q92889 1/20 0.49
GRM5 P41594 1/20 0.48
RIPK1 Q13546 1/20 0.47
MAPK1 P28482 1/20 0.46
LMNA P02545 1/20 0.46
ALDH1A1 P00352 3/20 0.45
TP53 P04637 1/20 0.45
HTT P42858 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
CHRNB2 P17787 2/20 0.43
CHRNA4 P43681 2/20 0.43
PDK1 Q15118 1/20 0.43
TBXAS1 P24557 1/20 0.43
DPP4 P27487 1/20 0.43
DPP8 Q6V1X1 1/20 0.43
DPP9 Q86TI2 1/20 0.43
CYP11B2 P19099 1/20 0.43
IDO1 P14902 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9926518 0.79 NPC1 (0.57) ERCC1ERCC4LMNAHTTNAMPT
SCHEMBL10991569 0.76 CHRNB2 (0.51) PYGLGRM5RIPK1MAPK1LMNA
Hydrochloric Acid SCHEMBL8542613 0.74 RIPK1 (0.58) PYGLRIPK1LMNAALDH1A1HTT
SCHEMBL6619359 0.74 RIPK1 (0.65) PYGLRIPK1LMNAALDH1A1CHRNB2
SCHEMBL25911142 0.72 ALDH1A1 (0.53) PYGLMAPK1LMNAALDH1A1HTT
SCHEMBL14753662 0.72 RIPK1 (0.66) PYGLRIPK1LMNAALDH1A1CHRNB2
SCHEMBL25911152 0.71 TP53 (0.54) MAPK1LMNAALDH1A1TP53HTT
SCHEMBL10995683 0.71 PDK1 (0.49) RIPK1MAPK1LMNAALDH1A1TP53
SCHEMBL5890987 0.71 LMNA (0.69) RIPK1LMNACHRNB2CHRNA4TBXAS1
SCHEMBL8057291 0.71 RIPK1 (0.64) RIPK1LMNAALDH1A1TP53CHRNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120149661-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS NOVARTIS AG (CH) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149661-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS MDM4, MDM2, TP53 PYGL 1679/4885ERCC1 1741/4885ERCC4 354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.